uniQure NV
QURE
23.14
+0.08
+0.35%
uniQure NV
US · QURE
#2954 by market cap
Listed 1970
23.14
+0.08
+0.35%
Live - 5344 symbols - heartbeat 282s ago
· 2026-10-08 07:00
Pre-market
23.10
-0.17%
After-hours
23.07
-0.30%
Overnight
22.85
-1.25%
- Market cap
- 1.61B
- P/E (TTM)i
- -5.70
- P/Bi
- 4.95
- EPSi
- -3.46
- Div yieldi
- 0.00%
- 52W posi
- 23%
Reader sentiment
Are you bullish or bearish on QURE?
Anonymous reader poll. Unscientific, not investment advice.
About uniQure NV
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.
- Founded
- 2012
- CEO
- Mr. Matthew C. Kapusta
- Employees
- 221
- Headquarters
- Amsterdam, Noord-Holland, Netherlands (the)
- Fiscal year end
- 12-31
- Website
- uniqure.com
Company profile
- Exchange
- US
- Symbol
- QURE
- Market-cap rank
- #2954
- Listing date
- 1970-01-01
- Market cap
- 1.61B
- Float cap
- 1.33B
- Shares out
- 69.37M
- Float shares
- 57.53M
Sectors & themes
Quote time 2026-10-08 07:00:00 · For reference only, not investment advice and not tailored to your situation.